INT315809

From wiki-pain
Revision as of 15:05, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.97
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (RTEL1) helicase activity (RTEL1) DNA binding (RTEL1)
Anatomy Link Frequency
B-cell 2
RTEL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
vincristine 1 38.52 Quite Low
positron emission tomography 6 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
imagery 3 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
Paracetamol 1 5.00 Very Low Very Low Very Low
Calcium channel 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 68 100.00 Very High Very High Very High
Cancer 13 99.98 Very High Very High Very High
Follicular Lymphoma 13 61.04 Quite High
Toxicity 16 60.48 Quite High
Acute Myeloid Leukemia 13 56.56 Quite High
Thrombocytopenia 8 53.48 Quite High
Neutropenia 5 52.64 Quite High
Diffuse Large B-cell Lymphoma 7 39.68 Quite Low
Disease 25 27.40 Quite Low
Syndrome 1 20.32 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, residual RTX remains in patients’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.


Regulation (control) of Protein_catabolism (grade) of NHL in B-cell associated with lymphatic system cancer and cancer
1) Confidence 0.03 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.97 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox